At a glance
ClinicalIndex Comparison RecordN/ACompleted· 204 enrolled
Drug / intervention
Afatinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
GioTag: Real-world Data Study on Sequential Therapy With Gi(l)Otrif®/ Afatinib as First-line Treatment Followed by Osimertinib in Patients With EGFR Mutation Positive Advanced Non-small Cell Lung Cancer
In Brief
An observational study evaluating Afatinib and Osimertinib for Carcinoma, Non-Small-Cell Lung. Completed, enrolled 204 participants across 1 site.
Detailed Summary
This is a non-interventional, multi-country, multi-centre cohort study based on existing data from medical records of patients with EGFR mutation-positive advanced NSCLC treated with afatinib (Gi(l)otrif®) as the first-line treatment followed by osimertinib in case the T790M resistance mutation was developed.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Non-Small-Cell Lung
CountriesAustria
Collaborators--
Timeline
N/ACompletedFinished
201820192020202120222023202420252026
First PostedDec 2017
Enrollment StartDec 2017
Primary CompletionNov 2019
TodayJul 2026
First PostedDec 12, 2017
Enrollment StartDec 28, 2017
Primary CompletionNov 28, 2019
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 8.6 years ago
Interventions
Afatinibdrug
GILOTRIF, GIOTRIF, XOVOLTIB
Osimertinibdrug
on T790M resistance mutation was developed